J&J, Dana-Farber ink $10M deal to develop lung cancer therapies
The Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) and J&J's Boston Innovation Center partnered with the Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science to develop immunotherapies for lung cancer. Under the three-year collaboration, the partners will determine the clinical setting for undisclosed immuno-oncology agents in Janssen's lung cancer discovery pipeline. The partners will use Belfer's immuno-oncology lung platform and models to assess the immunotherapies in conditions that "simulate the physical environment" of lung tumors.
As part of the collaboration, the partners will also identify drug combination strategies and biomarkers, characterize mechanisms of resistance, and identify and validate novel targets for lung cancers. J&J is providing $10 million in funding to the collaboration. ...